Your AI-Trained Oncology Knowledge Connection!
At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, discusses the use of lenalidomide, bortezomib, and dexamethasone with or without elotuzumab for newly diagnosed, high-risk multiple myeloma.
At 2022 ASCO, Paul G. Richardson, MD, reviewed the rationale of the phase 3 DETERMINATION study that set out to determine the benefit of lenalidomide maintenance with or without autologous stem transplantation in newly diagnosed multiple myeloma.
In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.
A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.
C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.
Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.
Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.
Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.
The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.
Transplant following lenalidomide, bortezomib, and dexamethasone with lenalidomide maintenance was superior to the treatment course without transplant, according to data at 2022 ASCO.
Elderly frail patients with relapsed/refractory multiple myeloma treated with ixazomib plus daratumumab experienced favorable response rates.
Data from the phase 2 IFM 2018-04 trial support the use of daratumumab, carfilzomib, lenalidomide, and dexamethasone coupled with tandem autologous stem cell transplant in eligible patients with high-risk multiple myeloma.
Induction/consolidation daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed RVd alone when it came to minimal residual disease and progression-free survival in patients with newly diagnosed, transplant-eligible myeloma.
Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.
High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.
Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.
Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.
Combining magrolimab with azacitidine led to manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large B-cell lymphoma.
A subgroup analysis of the phase 3 MAIA trial showed rapid, deep, and durable responses with daratumumab plus lenalidomide and dexamethasone vs standard therapy for newly diagnosed multiple myeloma across patient subgroups.
Amrita Y. Krishnan, MD, spoke about the use of teclistamab vs real-world data in patients with relapsed/refractory multiple myeloma.
Pacritinib had a comparable, if not superior, safety profile over best available therapy in patients with myelofibrosis, including those with low platelet counts.
Prior findings showing the benefit of brentuximab vedotin plus chemotherapy vs chemotherapy alone for the treatment of patients with previously untreated stage III/IV classical Hodgkin lymphoma was supported by 6-year updated overall survival data.
Results of the GEMSTONE-201 study demonstrate complete responses were achieved in roughly one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma who were treated with sugemalimab.
The combination of ibrutinib plus the chemotherapy bendamustine and rituximab immunotherapy elicited the highest PFS rate ever reported for this patient population, according to an expert.
Thierry Facon, MD, spoke about treatment combinations that have seen success in patients with multiple myeloma, as well as where future research should be focused.
Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.
